Mapping electrical properties in the brain

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates imaging methods to monitor neural and electrical activity in the brain, aiming to enhance clinical diagnosis of malignant glioma. The study focuses on optimizing MRI pulse sequences and developing models that depict the brain's electrical properties, such as resistivity and current. It also seeks to correlate these MRI models with existing imaging techniques and clinical features to improve understanding of neural integrity and function. Participants will complete a survey and undergo MRI scans as part of the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aim 1: normal healthy volunteers
* Aim 2, 3, 4: participants included in IRB 16-002424, including those that have undergone surgical biopsy/resection for suspected or known glioma

Exclusion Criteria:

* Healthy volunteer unable to have an MRI

Where it's running

• Mayo Clinic in Arizona
  Scottsdale, Arizona, United States Recruiting

Study contacts

• Principal investigator: Leland S. Hu, MD — Mayo Clinic
• Study coordinator: Clinical Trials Referral Office
• Email: mayocliniccancerstudies@mayo.edu
• Phone: 855-776-0015

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dual-target CAR-NK therapy for adults with recurrent or progressive glioblastoma and other high-grade gliomas

  This study will try giving dual-target CAR-NK cells into the surgical cavity to see if they can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07551336

• Dual-target CAR-NK cell therapy for recurrent glioblastoma and high-grade glioma

  This phase 1 study will test whether injecting dual-target CAR-NK cells into the brain is safe and can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07480941

• Retifanlimab With or Without DFMO for Progressive High-Grade Gliomas

  This trial tests whether retifanlimab, with or without DFMO, is safe and may help treat progressive high-grade gliomas in adults.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT07468136

• T2* MRI and blood tests to predict progression of malignant gliomas

  This trial tests whether T2* MRI scans and blood biomarkers can help predict how WHO grade IV malignant gliomas will change or come back in adults.

  Recruiting University of Iowa · Iowa City, Iowa · NCT07447531

• Investigating the effects of DFMO and AMXT 1501 on brain tumor metabolism

  This study is testing how two drugs, DFMO and AMXT 1501, can change the metabolism of brain tumors in patients after surgery.

  Recruiting Early Phase 1 Mayo Clinic · Rochester, Minnesota · NCT05717153

• Using CARv3-TEAM-E T Cells to treat glioblastoma

  This study is testing the best dose of a new type of immune cell treatment for people with glioblastoma, a serious brain cancer, to see how safe and effective it is.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT05660369

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.